B-Cure Laser

Company Overview

Snapshot

Founded in October 2007, B-Cure Laser operates with 11–50 employees. The company has raised $25.5M across one funding round. A significant milestone for the company was its public listing on TASE in May 2021.

Business overview

B-Cure Laser develops and markets medical devices for low-level laser therapy, offering portable, rechargeable, and user-friendly solutions. Its products are designed for the noninvasive treatment of pain, orthopedic conditions, wounds, burns, skin problems, inflammation, and sports injuries. Utilizing class-one lasers, these devices are sold over the counter and serve markets within the Health Tech & Life Sciences sector, specifically targeting medical devices and medical treatment & therapeutics.

Strategic signal

In March 2024, news emerged regarding the company's stock having collapsed by 96%, alongside reports of the chairman seeking a substantial salary package for a part-time position. This signals significant operational and financial challenges for B-Cure Laser, raising concerns among investors about leadership stability and the company's future trajectory.

Company Intelligence Q&A

What is B-Cure Laser's primary product offering?

B-Cure Laser provides a line of clinical low-level laser devices that are light, portable, rechargeable, and user-friendly. These devices are designed for the treatment of pain, orthopedic conditions, wounds, burns, skin problems, inflammation, and sports injuries.

When did B-Cure Laser go public?

B-Cure Laser became public on TASE in May 2021, raising $25.5M in capital.

What was the news regarding B-Cure Laser's stock performance in March 2024?

In March 2024, it was reported that B-Cure Laser's stock had collapsed by 96%, with the chairman reportedly seeking a salary package of nearly one million shekels for a part-time role.

What regulatory approval did B-Cure Laser receive in October 2021?

In October 2021, B-Cure Laser received approval from the Canadian Ministry of Health for its device.

What was the outcome of the Securities Authority's review of Erika B-Cure Laser in February 2024?

In February 2024, the Securities Authority initiated a review of Erika B-Cure Laser concerning European approvals.